Corvus Pharmaceuticals (FRA:C17) Total Equity: €208.19 Mil (As of Mar. 2026)


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
32 GF Score
Price €12.56
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Total Equity?

Corvus Pharmaceuticals FRA:C17 -0.75% 32 Total Equity is €208.19 Mil as of Mar. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Corvus Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was €208.19 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Corvus Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Total Equity Chart

Corvus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.99 52.97 35.47 31.10 52.27

Corvus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.63 69.56 61.15 52.27 208.19
FRA:C17
32GF Score
Corvus Pharmaceuticals Inc FRA:C17
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Corvus Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=60.736-8.467
=52.27

Corvus Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=219.014-10.826
=208.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €208.19 Mil mean?
Corvus Pharmaceuticals (FRA:C17) has a Total Equity of €208.19 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Corvus Pharmaceuticals and its competitors.
Is Corvus Pharmaceuticals' Total Equity too high?
Corvus Pharmaceuticals' current Total Equity is €208.19 Mil. Overall, Corvus Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Total Equity compare to LXRX and CGEM?
Corvus Pharmaceuticals' Total Equity of €208.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Total Equity is €208.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Total Equity of €208.19 Mil. The current Total Equity is €208.19 Mil. Corvus Pharmaceuticals' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Total Equity is €208.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
32GF Score

Get the complete analysis for FRA:C17

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.56
Price